Category: Emerging Medicine
In recognition of Atrial Fibrillation Awareness month, we wanted to highlight a few of the AF-related studies presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain.
Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions. Mavacamten is an investigational, first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.
Among the top-notch research presented at the American College of Cardiology 2022 Scientific Sessions was a small phase 1 trial that demonstrated big potential for a therapeutic that will lower lipoprotein [Lp(a)] and reduce atherosclerotic risk.
FDA Approves Empagliflozin for Heart Failure with Preserved Ejection Fraction. With this latest FDA approval, it’s time to get up to date on the newest treatments for heart failure. K2P is here to help.
Staying on top of emerging medicine is vital for providing the best care to patients and has multiple benefits for physicians. Staying on top of emerging medicine is vital for providing the best care to patients and has multiple benefits for physicians.
One of the several noteworthy trials presented at the virtual ESC Congress was the EAST-AFNET 4NET 4 trial, which was published concurrently in the New England Journal of Medicine.
A group of Italian researchers recently hypothesized that it is actually the endothelium that is being targeted by the COVID-19 virus.
COVID-19 does not always fit into the pattern of respiratory illness. While initially unexpected, clinicians and researchers are learning more each day that COVID-19 infection wears many disguises. In some victims, it clearly does not make its initial appearance as a respiratory virus.
Atrial Fibrillation: Scope of the Problem The prevalence of atrial fibrillation (AF) in the United States is estimated to rise from ≈5.2 million in 2010 to 12.1 million in 2030.…
Partnering with patients to assess their risk for cardiovascular disease can be a challenge. Developing a plan of care to manage hypertension is individualized; incorporating patient buy-in sets the stage…